The retinoblastoma gene family: Its role in cancer onset and progression

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 6, 2000, Pages 765-783

  Cinti, Caterina ^a   Giordano, Antonio ^b  

^a CNR   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

cell cycle; gene therapy; oncosuppressor gene; retinoblastoma gene family; tumourigenesis

Indexed keywords

EID: 0001375969     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.6.765     Document Type: Review

References (190)

1. ANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
2. RENAN MJ: How many mutations are required for tumorogenesis? Implications from human cancer data. Mol Carcinogenesis (1993) 7:139-146.
3. BERGERS G, HANAHAN D, COUSSES LM: Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorige-nesis. Int. J. Dev. Biol. (1998). 42:995-1002.
4. KINZLER KW, VOGELSTEIN B: Landscaping the cancer terrain. Science (1998) 280:1036-1037.
5. KNUDSON AG: Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA (1971) 68:820-823.
6. HAHN WC, COUNTER CM, LUNDBERG AS et al: Creation of human tumor cells with defined genetic elements. Nature (1999) 400:464-468.
7. Molecular Oncology. Bishop JM, Weinberg RA (Eds.), Scientific American, Inc., New York, USA (1996).
8. LASKOD, CAVENEE W, NORDENSKJOLD M: Loss of constitutional heterozygosity in human cancer. Ann. Rev. Genet. (1991) 25:281-314.
9. ZHU L, VAN DEN HEUVEL S, HELIN K et al: Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev. (1993) 7:1111-1125.
10. CLAUDIO PP, HOWARD CM, BALDI A et al: p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107
11. STAROSTIK P, CHOW KNB, DEAN DC: Transcriptional repression and growth suppression by the p107 pocket protein. Mol. Cell. Biol. (1996) 16:3606-3614.
12. CLAUDIO PP, HOWARD CM, PACILIO C et al: Mutations in the retinoblastoma-related gene Rb2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res. (2000) 60:372-382.
13. HUANG HJ, YEE JK, SHEW JY et al: Suppression of the neoplastic phenotype by replacement of the Rb gene in human cancer cells. Science (1988) 242:1563-1566.
14. CAVENEE WK, HANSEN MF, NORDENSKJOLD M et al: Genetic origin of mutations predisposing to retinoblastoma. Science (1985) 228:501-503.
15. BALDI A, BOCCIA V, CLAUDIO PP, DE LUCA A, GIORDANO A: Genomic structure of the human retinoblastoma-related Rb2/p130 gene. Proc. Natl. Acad. Sci. USA (1996.) 93:4629-4632.
16. YEUNG RS, BELL DW, TESTA JR et al.: The retinoblastoma-related gene, Rb2, maps to human chromosomes 16q12 and rate chromosome 19. Oncogene (1993) 8:3465-3458.
17. WEINBERG RA: Tumor suppressor genes. Science (1991) 254:1138-1145.
18. MASCIULLO V, KHALILI K, GIORDANO A: The Rb family of cell cycle regulatory factors: clinical implications. Int. J. Oncol. (2000) 17:897-902.
19. SANG N, BALDI A, GIORDANO A: The roles of tumor suppressors pRb and p53 in cell proliferation and cancer. Mol. Cell. Diff. (1995) 3:1-29.
20. BIGGS PJ, WOOSTER R, FORD D et al: Familial cylindro-matosis (turban tumor syndrome) gene localised to chromosome 16q12-q13: evidence for its role as tumor suppressor gene. Nature Genet (1995) 11:441-443.
21. CINTI C, CLAUDIO PP, HOWARD CM et al: Genetic alteration disrupting the nuclear localization of the retinoblastoma-related gene of Rb2/p130 in human tumor cell lines and primary tumors. Cancer Res. (2000) 60:383-389.
22. CINTI C, LEONCINI L, NWONGO A et al: Genetic alterations of the retinoblastoma related gene Rb2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am. J. Pathol (2000) 156:751-760.
23. CLAUDIO PP, HOWARD CM, FU Y et al: Mutations in the retinoblastoma- related gene Rb2/p130 in primary nasopharyngeal carcinoma. CancerRes. (2000) 60:8-12.
24. LEVINE AJ: The tumor suppressor genes. Ann. Rev Biochem. (1993) 62:623-651.
25. WEINBERG RA: The retinoblastoma protein and cell cycle control. Cell (1995) 81:323-330.
26. PAGGI MG, BALDI A, BONETTO F, GIORDANO A: Retinoblastoma protein family in cell cycle and cancer. A review. J. Cell. Biochem. (1996) 62:418-430.
27. MAYOL X, GRANA X, BALDI A, SANG N, HU Q, GIORDANO A: Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene (1993) 8:2561-2566.
28. EWEN ME, XING EW, LAWRENCE JB, LIVINSTON D: Molecular cloning, chromosomal mapping and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell (1991) 66:1155-1164.
29. HANNON GJ, DEMERICK D, BEACH D: Isolation of the Rb-related p130 through its interaction with cdk2 and cyclins. GenesDev. (1993) 7:2378-2391.
30. LI Y, GRAHAM C, LACY S, DUNCAN AMV, WHYTE P: The adenovirus E1A-associated 130-kd protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E in a temporally distinct manner. Genes Dev. (1993) 7:2366-2377.
31. LEE JO, RUSSO AA, PAVLETICH NP: Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature (1998) 391:859-865
32. TAYA Y: Rb kinase and Rb-bindingproteins: new point of view. Trends Biol Sci. (1997) 21:14-17.
33. PURI PL, MACLACHLAN TK, LEVRERO M, GIORDANO A: The intrinsic cell cycle: from yeast to mammal. In: The Molecular Basis of Cell Cycle and Growth Control. Stein GS, Baserga R, Giordano A, Denhardt DT (Eds.), Wiley-Liss, New York, USA (1999):15-79.
34. DYSON N: The regulation of E2F by pRB-family proteins. Genes Dev. (1998) 12:2245-2262.
35. LUO RX, POSTIGO AA, DEAN DC: Rb interacts with histone deacetylase to repress transcription. Cell (1998) 92:463-473.
36. BREHM A, MISKAEA, MCCANCEDJ et al: Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 391:597-601.
37. STIEGLER P, DE LUCA A, BAGELLA L, GIORDANO A: The COOH-terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter. Cancer Res. (1998) 58:5049-5052.
38. MAGNAGHI-JAULIN L, GROISMAN R, NAGUIBNEBA I et al: Retinoblastoma protein represses transcription by recruiting histone deacetylase. Nature (1998) 391:601-604.
39. WHITAKER LL, SU H, BASKARAN R, KNUDSEN ES, WANG JY: Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket. Mol Cell. Biol. (1998) 18:4032-4042.
40. HU Q, DYSON N, HARLOW E: The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBOJ. (1990) 9:1147-1155.
41. HUANG S, WANG N-P, TSENG BY, LEE WH, LEE EH-HP: Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. EMBO J. (1990) 9:1815-1822.
42. DE LUCA A, MACLACHLAN TK, BAGELLA L et al: Aunique domain of pRb2/p130 acts as inhibitor of cdk2 kinase activity. J. Biol Chem. (1997) 272:20971-20974.
43. CHU WM, WANG Z, ROEDER RG, SCHMID CW J: RNA polymerase III transcription repressed by Rb through its interactions with TFIIIB and TFIIIC2. J. Biol Chem. (1997) 272:14755-14761.
44. WHITE RJ, TROUCHE D, MARTIN K, JACKSON SP, KOUZARIDES T: Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature (1996) 382:88-90.
45. SUTCLIFFE JE, CAIRNS CA, MCLEES A et al: RNA polymerase III transcription Factor IIIB is a target for repression by pocket proteins p107 and p130. Mol Cell. Biol (1999) 19:4255-4261.
46. JOHNSON DG, SCHNEIDER-BROUSSARD R: Role of E2F in cell cycle control and cancer. Front Biosci. (1998) 3:D447-D458.
47. WU CL, ZUKERBERG LR, NGWU C, HARLOW E, LEES JA: In vivo association of E2F and DP family proteins. Mol Cell. Biol (1995) 15:2536-2546.
48. ADAMS PD, KAELIN WG, JR.: Transcriptional control by E2F. Semin. Can. Biol. (1995) 6:99-108.
49. QIAN Y, LUCKEY C, HORTON L, ESSER M, TEMPLETON DJ: Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol. Cell. Biol. (1992) 12:5363-5372.
50. QUIN XQ, CHITTENDEN T, LIVINGSTON D, KAELIN WG: Identification of a growth suppressor domain within the retinoblastoma gene product. Genes Dev. (1992) 6:953-964.
51. HIEBERT SW: Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factors are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol. Cell. Biol. (1993) 13:3384-3391.
52. RAYCHADHURY P, BAGCHI S, DEVOTO SH et al.: Domains of the adenovirus E1A protein that are required for oncogenic activity are also required for dissociation of E2F transcription factor complex. Genes Dev. (1991) 5:1200-1211.
53. KAYE FJ, KRATZKE RA, GERSTER JL, HOROWITZ JM: A single amino acid substitution results in a retinoblas-toma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA (1990) 87:6922-6926.
54. HOROWITZ JM, YANDELL DW, PARK SH et al.: Point mutational inactivation of the retinoblastoma antion-cogene. Science (1989) 243:937-940.
55. CHITTEDEN T, LIVINGSTON DM, KAELIN WG: The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein. Cell (1991) 65:1071-1082.
56. HIEBERT SW, CHELLAPPAN SP, HOROWITS JM, NEVINS JR: The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. (1992) 6:177-185.
57. SLANSKY JE, FARNHAM PJ: Introduction to the E2F family: protein structure and gene regulation. Curr. Top. Microbiol. Immunol. (1996) 208:1-30.
58. CLAUDIO PP, CAPUTI M, GIORDANO A: Gene therapy models. The Rb2/p130 gene: the latest weapon in the war against lung cancer? Clin. Canc. Res. (2000) 6:754-764.
59. VAIRO G, LIVINGSTON DM, GINSBERG D: Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppressor by different retinoblastoma protein family members. Genes Dev. (1995) 9:869-881.
60. GINSBERG D, VAIRO G, CHITTENDEN T et al.: E2F4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev. (1994) 8:2665-2679.
61. MOBERG K, STARTS MA, LEES JA: E2F4 switches from p130 top107 and pRb in responseto cell cycle reentry. Mol. Cell. Biol. (1996) 16:1436-1449.
62. HIJMANS EN, VOORHOEVE PM, BEIJERSBERGEN RL, VAN 'T VEER LJ, BERNARDS R: E2F5, a new E2F family member that interacts with p130 in vivo. Mol. Cell. Biol. (1995) 15:3082-3089.
63. LINDEMAN GJ, GAUBATZ S, LIVINGSTON DM, GINSBERG D: The subcellular localization of E2F-4 is cell-cycle dependent. Proc. Natl. Acad. Sci. USA (1997) 94:5095-5100.
64. . DE LA LUNA S, BURDEN MJ, LEE C-W, LA THANGUE NB: Nuclear accumulation of the E2F heterodimer regulated by subunit composition and alternative splicing of a nuclear localization signal. J. Cell Sci. (1996) 109:2443-2452.
65. MAGAE J, WU C-L, ILLENYE S, HARLOW E, HEINTZ NH: Nuclear localization of DP and E2F transcription factors by heterodimeric patterns and retinoblastoma protein family members. J. Cell Sci. (1996) 109:1717-1726.
66. PURI PL, CIMINO L, FULCO M et al: Regulation of E2F4 mitogenic activity during terminal differentiation by its heterodimerization partners for nuclear translocation. Cancer Res. (1998) 58:1325-1331.
67. COBRINIK D, WHYTE P, PEEPER DS, JACKS T, WEINBERG RA: Cell cycle specific association of E2Fwith the p130 E1A-binding protein. Genes Dev. (1993) 7:2392-2404.
68. JOHNSON DG: Regulation of E2F1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene (1995) 11:1685-1692.
69. ZHU L,XIEE, CHANG LS: Differential role of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins. Mol. Cell. Biol (1995) 15:3552-3562.
70. CHELLAPPAN SP: The E2F transcription factor: role of the cell cycle regulation and differentiation. Mol. Cell. Differ. (1994) 2:201-220.
71. JOHNSON DG, CRESS WD, JAKOI L, NEVINS JR: Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. USA (1994) 91:12823-12827.
72. SINGH P, WONG S, HONG W: Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBOJ. (1994) 13:3329-3338.
73. XU G, LIVINGSTON DM, KREK W: Multiple members of the E2Ftranscription factor family are the products of oncogenes. Proc.Natl. Acad. Sci. USA (1995) 92:1357-1361.
74. YAMASAKI L, JACKS T, BRONSON R et al: Tumor induction and tissue atrophy in mice lacking E2F-1. Cell (1996) 85:537-548.
75. PIERCE AM, FISHER SM, CONTI CJ, JOHNSON DG: Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene (1998) 16:1267-1276.
76. PIERCE AM, GIMENEZ-CONTI IB, SCHNEIDER-BROUSSARD R et al: Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc. Natl. Acad. Sci. USA (1998) 95:8858-8863.
77. MORAN E: DNAtumor virus transformingproteins and the cell cycle. Curr. Opin. Genet. Dev. (1993) 3:63-70.
78. DECAPRIO JA, LUDLOW JW, FIGGE J et al.: SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell (1988) 54:275-283.
79. DYSON N, HOWLEY PM, MUENGER K, HARLOW E: The human papilloma virus-16 E7 oncoprotein is able to bindtothe retinoblastoma geneproduct. Science (1989) 243:934-937.
80. WHYTE P, BUCKOVICH KJ, HOROWITZ JMet al.: Association between an oncogene and an antioncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (1988) 334:124-127.
81. WHYTEP,WILLIAMSON NM, HARLOWE: Cellular targets for transformation by the adenovirus E1A proteins. Cell (1989) 56:67-75.
82. STUBDAL H, ZALVIDE J, DECAPRIO JA: Simian virus 40 large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107. J. Virol. (1996) 70:2781-2788.
83. GIORDANO A, LEE JH, SCHEPPLER JA et al.: Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A. Science (1991) 253:1271-1275.
84. SLEBO RJ, LEE MH, PLUNKETT BS et al.: p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA (1994) 91:5320-5324.
85. STUBDAL H, ZALVIDE J, CAMPBEL KS et al.: Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol. Cell. Biol. (1997) 17:4979-4990.
86. CHEN S, PAUCHA E: Identification of the region of simian virus 40 large T antigen required for cell transformation. J. Virol. (1990) 64:3350-3357.
87. EGAN C, BAYLEY ST, BRANTON PE: Binding of the Rb1 protein to E1A products is required for adenovirus transformation. Oncogene (1989) 4:383-388.
88. MORAN E, ZERLER B, HARRISON TM, MATHEWS MB: Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes. Mol. Cell. Biol. (1986) 6:3470-3480.
89. WHYTE P, RULEY HE, HARLOW E: Two regions of the adenovirus early reaction 1A protein are required for transformation. J. Virol. (1988) 62:257-265.
90. BAGCHI S, RAYCHAUDHURI P, NEVINS JR: Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell (1990) 62:659-669.
91. NEVINS JR: E2F: a link between Rb tumor suppressor protein and viral oncoproteins. Science (1992) 258:424-429.
92. KAELIN WG, EWEN ME, LIVINGSTON DM: Definition of the minimal simian virus 40 large T antigen and adenovirus E1A-binding domain in the retinoblatoma gene product. Mol. Cell. Biol (1990) 10:3761-3769.
93. DINGWALL C, LASKEY RA: Nuclear targeting sequences: a consensus? Trends Biol. Sci. (1991) 16:478-481.
94. ZACKSENHAUS E, BREMNER R, PHILLIPS RA, GALLIE BL: A bipartite nuclear localization signal in the retinoblas toma gene product and its importance for biological activity. Mol. Cell. Biol. (1993) 13:4588-4599.
95. THOMAS RC, EDWARS MJ, MARKS R: Translocation of the retinoblastoma gene product during mitosis. Exp. Cell Res. (1996) 223:227-232.
96. GRUMSTEIN M: Histone acetylation in chromatin structure and transcription. Nature (1997) 389:349-352.
97. WOO MS-A, SANCHEZ I, DYNLACHT BD: p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity. Mol. Cell. Biol. (1997) 17:3566-3579.
98. HERRMANN CH, SU LK, HARLOW E: Adenovirus E1A is associated with a serine/threonine protein kinase. J. Virol. (1991) 65:5848-5859.
99. KNUDSEN ES, WANG JYJ: Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. (1996) 271:8313-8320.
100. SHIRODKAR S, EWEN M, DECAPRIO JA et al.: The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell (1992) 66:157-166.
101. BALDI A, DE LUCA A, CLAUDIO PP et al.: The Rb2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. J. Cell. Biochem. (1995) 59:402-408.
102. PHILLIPS A, HUET X, PLET A et al: The retinoblastoma protein is essential for cyclin A repression in quiescent cells. Oncogene (1998) 16:1373-1381.
103. DONG F, CRESS WD JR, AGRAWAL D, PLEDGER WJ: The role of cyclin D3-dependent kinase in the phosphorylation of p130 in mouse BALB/c 3T3 fibroblasts. J. Biol Chem. (1998) 273:6190-6195.
104. BONETTO F, FANCIULLI M, BATTISTA T et al: Interaction between the pRb2/p130 C-terminal domain and N-terminal portion of cyclin D3. J. Cell Biochem. (1999) 75:698-709.
105. DOWDY SF, HINDS PW, LOUIS K et al: Physical interac tion of retinoblastoma protein with human D cyclin. Cell(1993) 73:499-511.
106. CLAUDIO PP, DE LUCA A, HOWARD CM et al: Functional analysis of pRb2/p130 interaction with cyclins. Cancer Res. (1996) 56:2003-2008.
107. BARTEK J, BARTKOVA J, LUKAS J: The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. (1996) 8:805-814.
108. WHYTEP:The retinoblastoma protein and its relatives. Semin. Cancer. Biol. (1995) 6:83-90.
109. HOWARD CM, CLAUDIO PP, DE LUCA A et al: Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27kip1 and cyclin Enegative feedback regulatory loop. Cancer Res. (2000) 60:2737-2744.
110. SELLERS WR, KAELIN WG, JR.: Role of the retinoblas toma protein in the pathogenesis of human cancer. J. Clin. Oncol. (1997) 15:3301-3312.
111. SERRANO M, LEE HW, CHIN L et al: Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 85:27-37.
112. DENG C, ZHANG P, HARPER P et al.: Mice lacking p21 CIP/WAF1 undergo normal development, but are defective in the G1 checkpoint control. Cell (1995) 82:675-684.
113. FERO ML, RIVKIN M, TASCH M et al: A syndrome of multiorgan hyperplasia with features of gigantism tumorigenesis and female sterility in p27Kip1-deficent mice. Cell (1996) 85:733-744.
114. NAKAYAMA K, ISHIDA N, SHIRANE M et al.: Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell (1996) 85:707-720.
115. HARBOUR JW, LUO RX, DEI SANTI A, POSTIGO AA, DEAN DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell (1999) 98:859-869.
116. SHERR CJ, ROBERTS JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. (1995) 9:1149-1463.
117. ZHU L, HARLOW E, DYNLACHT BD: p107 uses a p21CIP-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev. (1995) 9:1740-1752.
118. LUNDBERG AS, WEINBERG RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. (1998) 18:753-761.
119. STIEGLER P, KASTEN M, GIORDANO A: The RB family of cell cycle regulatory factors. J. Cell. Biochem. Suppl (1998) 30-31:30-36.
120. THOMAS NSB, PIZZEY AR, TIWARI S, WILLIAMS CD, YANG J: p130, p107 and pRb are differentially regulated in proliferating cells and during cell cycle arrest by "/-interferon. J. Biol. Chem. (1998) 273: 23659-23667.
121. NEVINS JR: Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. (1998) 9:585-593.
122. FLEMINGTON EK, SPECK SH, KAELIN WG, JR.: E2F1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA (1993) 90:6914-6918.
123. HELIN K, HARLOW E, FATTAEY A: Inhibition of E2F1 transactivation by direct binding of the retinoblastoma protein. Mol. Cell. Biol. (1993) 13:6501-6508.
124. SELLERS WR, RODGERS JW, KAELIN WG, JR.: A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. USA (1995) 92:11544-11548.
125. HARBOUR JW, DEAN DC: Rb function in cell-cycle regulation and apoptosis. Nature Cell. Biol. (2000) 2:65-67.
126. MORRIS L, ALLEN KE, LA THANGUE NB: Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators. Nature Cell Biol. (2000) 2:232-239.
127. STIEGLER P, GIORDANO A: Big brothers are watching: the retinoblastoma family and growth control. In: Molecular and Subcellular Biology. Marcello-Colheiro (Ed.), Springer-Verlag, New York, USA (1998):24-42.
128. SELLER WR, KAELIN WG: Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol. (1997)15:3301-3312.
129. HOSHIKAWA Y, MORI A, AMIMOTO K, IWABE K, HATAKEYAMA M: Control of retinoblastoma protein-independent hematopoietic cell cycle by the pRB-related p130. Proc. Natl. Acad. Sci. USA (1998) 95:8574-8579.
130. MULLIGAN GJ, WONG J, JACKS T: p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRb. Mol. Cell Biol. (1998) 18:206-220.
131. HINDS PW, MITTNACHT S, DULIC V et al: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell (1992) 70:993-1006.
132. LACY S, WHYTE P: Identification of p130 domain mediating interactions with cyclin A/cdk2 and cyclin E/cdk2 complexes. Oncogene (1997) 14:2395-2406.
133. HOWARD CM, CLAUDIO PP, GALLIA GL, GORDON J, GIORDANO A: Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo. J. Nature Cancer Inst. (1998) 90:1415-1460.
134. ZHU L, ENDERS G, LEES JA et al: The pRb-related protein p107 contains two growth suppressor domains: independent interaction with E2F and cyclin/cdk complexes. EMBOJ. (1995) 14:1904-1913.
135. JACOBSON MD, WEIL M, RAFF MC: Programmed cell death in animal development. Cell. (1997) 88:347-354.
136. EVAN JN, BROWN L, WHYTE M, HARRINGTON E: Apoptosis and cell death. Curr. Opin. Cell Biol. (1995) 7:825-834.
137. ENOCH T, NORBURY C: Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem. Sci. (1995) 20:426-430.
138. LEVINE A: p53 the cellular gatekeeper for growth and division. Cell (1997) 88:323-331.
139. KASTEN MM, GIORDANO A: pRb and cdks in apoptosis and cell cycle. Cell Death Differ. (1998) 5:132-140.
140. TSAIKY, HU Y, MACLEOD KF, CROWLEY D, YAMASAKI L, JACKS T: Mutation of E2F1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell. (1998) 2:293-304.
141. HAAS-KOGAN DA, KOGAN SC, LEVI D et al.: Inhibition of apoptosis by the retinoblastoma gene product. EMBOJ. (1995) 14:461-472.
142. KRANENBURG O, VAN DER EB AJ, ZANTEMA A: Cyclin D1 is an essential mediator of neuronal cell death. EMBO J. (1996) 15:46-54.
143. HAN EK, BEGEMANN M, SGAMBATO A et al.: Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth and enhances apoptosis. Cell Growth Differ (1996) 7:699-710.
144. LAHTI JM, XIANG J, HEATH LS, CAMPANA D, KIDD J: PITSLRE protein kinase activity is associated with apoptosis. Mol. Cell. Biol. (1995) 15:1-11.
145. LEE MH, WILLIAMS BO, MULLIGAN G et al: Targeted disruption of p107: functional overlap between p107 and Rb. GenesDev. (1996) 16:1621-1632.
146. WANG J, GUO K, WILLS KN, WALSH K: Rb functions to inhibit apoptosis during myocyte differentiation. Cancer Res. (1997) 57:351-354.
147. CARNAC G, FAJAS L, L'HONORE A et al.: The retinoblastoma-like protein p130 is involved in the determination of reserve cells in differentiating myoblasts. Curr. Biol. (2000) 10:543-546.
148. BALDI A, ESPOSITO V, DE LUCA A et al.: Differential expression of pRb2/p130 andp107 in normal human tissues and in primary lung cancer. Clin. Cancer. Res. (1997) 3:1691-1697.
149. MULLIGAN G, JACKS T: The retinoblastoma gene family: cousins with overlapping interests. Trends Genet. (1998) 14:223-229.
150. LEE EYHP, HU H, YUAN SSF et al: Dual roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation. Genes Dev. (1994) 8:2008-2021.
151. CALLAGHAN DA, DONG L, CALLAGHAN SM et al: Neural precursor cells differentiating in the absence of Rb exhibit delayed terminal mitosis and deregulated E2F 1 and 3 activity. Dev. Biol (1999) 207:257-270.
152. LECOUTER JE, KABLAR B, WHYTE PF, YING C, RUDNICKI MA: Strain-dependent embryonic lethality in mice lacking the retinoblastoma-related p130 gene. Development (1998) 23:4669-4679.
153. MORI A, HIGASHI H, HOSHIKAWA Y, IMAMURA M, ASAKA M, HATAKEYAMA M: Granulocytic differentiation of myeloid progenitor cells by p130, the retino-blastoma tumor suppressor homologue. Oncogene (1999) 18:6209-6221.
154. LI ZR, HROMCHAK R, MULTIPALLI A, BLOCH A: Tumor suppressor proteins as regulators of cell differentiation. Cancer. Res. (1998) 58:4282-4287.
155. RASCHELLA G, TANNO B, BONETTO F et al.: The Rb-related gene Rb2/p130 in neuroblastoma differentiation and in B-myb promoter down-regulation. Cell. Death Differ (1998) 5:401-407.
156. SHENG Q, LOVE TM, SCHAFFHAUSEN BJ: Domain-independent regulation of the Rb family by polyoma-virus large T antigen. J. Virol. (2000) 74:5280-5290.
157. VOGELSTEIN B, KINZLER KW: The multistep nature of cancer. Trends Genet. (1993) 9:138-141.
158. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86:353-364.
159. RAK J, MITSUHASHI Y, SHEEHAN C et al.: Collateral expressionof proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis. Neoplasia (1999) 1:23-30.
160. STIEGLER P, LOTAN R, GIORDANO A: From cell cycle regulationtoangiogenesis: dialogue between the basic and clinical sciences. J. Cell. Physiol. (1999) 179:233-236.
161. ROBERTS DD: Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. (1996) 10:1183-1191.
162. HOLMGREN L, JACKSON G, ARBISER J: p53 induces angiogenesis restricted dormancy in mouse fibrosar-coma. Oncogene (1998) 17:819-824.
163. DAMERON KM, VOLPERT OV, TAINSKY MA, BOUCK N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 265:1582-1584.
164. SALNIKOW K, COSENTINO S, KLEIN C, COSTA M: Loss of thrombospondin transcriptional activity in nickel-transformed cells. Mol. Cell Biol. (1994) 14:851-858.
165. HARADA H, NAKAGAWAK,IWATA Set al.: Restorationof wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer. Res. (1999) 59:3783-3789.
166. ZHANG Y, GRIFFITH EC, SAGE J et al.: Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc. Natl. Acad. Sci. USA (2000) 97:6427-6432.
167. HALL M, PETERS G: Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancer. Adv. Cancer Res. (1996) 68:67-108.
168. KHATIB ZA, MATSUSHIME H, VALENTINE M, SHAPIRO DN, SHERR CJ, LOOK AT: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. (1993) 53:5535-5541.
169. HE J, ALLEN JR, COLLINS VP et al.: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. (1994) 54:5804-5807.
170. WOLFEL T, HAUER M, SCHNEIDER J et al: Ap16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 269:1281-1214.
171. KOH J, ENDERS GH, DYNLACHT BD, HARLOW E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (1995) 375:506-510.
172. LUKAS J, PARRY D, AAGAARD L et al: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (1995) 375:503-506.
173. MINIMO C, BIBO M, CLAUDIO PP, DE LUCA A, GIORDANO A: The role of pRb2/p130 protein in diagnosing lung carcinoma on fine needle aspiration biopsies. Pathol. Res. Pract. (1999) 195:67-70.
174. SUSINI T, BALDI F, HOWARD CM et al.: Expression of the retinoblastoma related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J. Clin. Oncol. (1998)16:1085-1093.
175. MASSARO-GIORDANO M, BALDI G, DE LUCA A, BALDI A, GIORDANO A: Differential expression of the retinoblastoma gene family members in choroidal melanoma: prognostic significance. Clin. Cancer Res. (1999) 5:1455-1458.
176. LEONCINI L, BELLAN C, COSSU A et al: Retinoblastoma-related p107 and pRb2/p130 proteins in malignant lymphomas: distinct mechanisms of cell growth control. Clin. Cancer Res. (1999) 5:4065-4072.
177. ICHIMURA K, HANAFUSA H, TAKIMOTO1 H et al: Structure of the human retinoblastoma-related p107 gene and its intragenic detection in a B-cell lymphoma cell line. Gene (2000) 251:37-43.
178. SALGIA R, SKARIN AT: Molecular abnormalities in lung cancer. J. Clin. Oncol (1998) 16:1207-1217.
179. SHIMIZU E, COXON A, OTTERSON GA et al: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma and mesothelioma. Oncogene (1994) 9:2441-2448.
180. HELIN K, HOLM K, NIEBUHR A et al: Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc. Natl. Acad. Sci. USA (1997) 94:6933-6938.
181. SLAGIA R, SKARIN AT: Molecular abnormality in lung cancer. J. Clin. Oncol (1998) 16:1207-1217.
182. DOSAKA-AKITA H, HU SX, FUJINO M et al: Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer (1997) 79:1329-1337.
183. SHAPIRO GI, ROLLINS BJ: p16INK4Aas a human tumor suppressor. Biochim.Biophys. Acta. (1996) 1242:165-169.
184. XU HJ, HU SX, CAGLE PT, MOORE GE, BENEDICT WF: Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res. (1991) 51:2735-2739.
185. BIGNON YJ, RIO P: The retinoblastoma gene: will therapeutic use of its tumor suppressor properties be possible? Bull. Cancer. (1993) 80:704-712.
186. ZUR HAUSEN H: Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta. (1996) 1288:F55-F78.
187. PROCOPIO A, STRIZZI L, GIUFFRIDA A et al: Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy. Monaldi Arch. Chest Dis. (1998) 53:241-243.
188. MUTTI L, DE LUCA A, CLAUDIO PP et al: Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma. Dev. Biol. Stand. (1998) 9:47-53.
189. PUPA SM, HOWARD CM, INVERNIZZI AM et al: Ectopic expression of pRb2/p130 suppresses the tumorigen-icity of the c-erbB-2-overexpressing SKOV3 tumor cell line. Oncogene (1999) 18:651-656.
190. PARR MJ, MANOME Y, TANAKA T et al: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nature Med. (1997) 3:1145-1149.